Medullary thyroid cancer

Summary of opinion: Retsevmo Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Eli Lilly, NSCLC, MTC, Committee, RET, Lung cancer, Medication package insert, Selpercatinib, Iodine, European Commission, Marketing, CHMP, Medullary thyroid cancer

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.
  • The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.
  • The CHMP adopted a new indication as follows:
    Retsevmo as monotherapy is indicated for the treatment of adults with:
    - advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1).
  • 1New text in bold.

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Retrieved on: 
Wednesday, April 3, 2024
Community, Eurostat, Civil service commission, Thyroid cancer, Diagnosis, Metabolism, Diarrhea, Enzyme, Hormone, Growth, Thyroid hormones, Prevalence, Cell, Calcitonin, Disease, Patient, Malignancy, Committee, Knowledge, Tissue, Seriousness, Doxorubicin, Boulogne-Billancourt, Regulation, Cancer, EMA, IRIS, Thyroid neoplasm, Cabozantinib, Protein, Medullary thyroid cancer, Thyroid, European, COMP, Iodine, European Commission, Safety, Blood, Marketing, Human, Pharmaceutical industry

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Key Points: 


Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

LUNGevity and RETpositive Issue RFA for Pan-Cancer Research Focused on RET Biomarker

Retrieved on: 
Thursday, January 25, 2024
Medullary thyroid cancer, Patient, Papillary thyroid cancer, Thought, Research, Cancer, Lung cancer, RET, Doctor of Philosophy, Biomarker, MPH, Breast, RFA, Pharmaceutical industry

WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation is proud to announce the 2024 Request for Applications (RFA) for our first pan-cancer research award program—the RETpositive/LUNGevity Translational Research Award for RET-positive Cancer.

Key Points: 
  • WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- LUNGevity Foundation is proud to announce the 2024 Request for Applications (RFA) for our first pan-cancer research award program—the RETpositive/LUNGevity Translational Research Award for RET-positive Cancer.
  • Currently, two RET tyrosine kinase inhibitors are approved for the treatment of cancers carrying the RET biomarker.
  • In this award program, RETpositive, a patient-led advocacy group focused on increasing awareness and supporting research for RET-positive cancers, seeks to fund high-impact research that transforms the future for all patients diagnosed with RET-positive cancer by changing RET-positive cancer into a chronic or curable condition.
  • RETpositive and LUNGevity successfully partnered in 2022 to fund research focused on RET-positive lung cancer.

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023
Lung, Lutetium (177Lu) oxodotreotide, Seed, EANM, Patient, Clinical study report, Research, Radiation therapy, Marketing, Stony Brook University, UPMC Hillman Cancer Center, Medullary thyroid cancer, Growth, Congress, University, Fortis Healthcare, Pelvic exenteration, Radiation, PRRT, Toxicity, IND, GEP-NET, MTC, Melanoma, Perspective, CATX, Communication, NET, Society, ASTRO, Therapy, NETS, Wilfrid Sellars, Brain, Biology, Nuclear Medicine and Biology, Glomus tumor, NYSE, PET/CT, SPECT/CT, Clinical trial, MC1R, Prostate cancer, NIH, Survival, UPMC, GEP, Rare-earth element, Medical imaging, Pharmaceutical industry, Medical device, Cryptocurrency, Nuclear medicine, Brachytherapy

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

Sino Biopharm (1177.HK) Announces 2022 Annual Results

Retrieved on: 
Friday, March 31, 2023
Intellectual property, Medicine, Hepatitis, Bioeconomy, Health, BIC, NASH, Marketing, Liver disease, COVID-19, Reform, Respiratory system, Research, Sino Biopharmaceutical Limited, The Company, Patent, Risk, FIC, Medullary thyroid cancer, Phase, Thyroid cancer, Country, PL-5, Medical imaging, Vaccine, Pharmaceutical industry, PRC

HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022.

Key Points: 
  • HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2022.
  • To date, the product has been approved for two indications: third-line classic Hodgkin's lymphoma and first-line squamous non-small cell lung cancer.
  • Phase III clinical trials have been completed with marketing applications submitted in China and the United States.
  • With its strong oncology sales team, Sino Biopharm is confident in a smooth launch and rapid market penetration of the product.

Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor

Retrieved on: 
Wednesday, December 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Monroe Dunaway Anderson, MTC, Drug, NMPA, IND, UCLA, Partnership, Medullary thyroid cancer, Patient, RET, Cancer, NSCLC, Thyroid, Serotonin reuptake inhibitor, CMO, SRI, Clinical trial, University, Safety, University of Kentucky, Neoplasm, Pharmaceutical industry, EU, Ellipses

Ellipses Pharma (Ellipses), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of a patient in EP0031-101, a trial investigating Ellipses next generation selective RET inhibitor (SRI) EP0031.

Key Points: 
  • Ellipses Pharma (Ellipses), a global drug development company focused on accelerating the development of new oncology treatments, today announces the first dosing of a patient in EP0031-101, a trial investigating Ellipses next generation selective RET inhibitor (SRI) EP0031.
  • Next generation SRIs offer the potential to expand the armamentarium against RET-driven cancers and further improve patient outcomes.
  • We are pleased that the EP0031-101 trial has dosed the first patient in the United States and congratulate our partner Ellipses on this important milestone.
  • EP0031 is a potent next generation SRI with broad activity against common RET fusions and mutations, including solvent front resistance mutations.

ALX Oncology Appoints Scott Garland to its Board of Directors

Retrieved on: 
Tuesday, November 29, 2022
Medullary thyroid cancer, SAN, Fondaparinux, Chief commercial officer, Triple accreditation, Alexion, Biotechnology, Therapy, Patient, CD47, Hyperkalemia, Lymphatic system, Security (finance), ALX, FC, Cancer, Research, Duke University, Genentech, California Polytechnic State University, Fuqua School, Bachelor of Science in Nursing, Business, Pharmaceutical industry, Portola Pharmaceuticals, Exelixis

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the Board) effective November 29, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the Board) effective November 29, 2022.
  • Scott is a biopharmaceutical industry leader who brings broad commercial, portfolio management, and leadership experience to the Board, said Corey Goodman, Ph.D., Executive Chairman of ALX Oncology.
  • On behalf of the Board and our executive leadership team, we welcome Scott and look forward to his contributions.
  • Mr. Garland sits on the Board for Day One Biopharmaceuticals and Calithera Biosciences, and formerly sat on the Board of Karyopharm Therapeutics.

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

Retrieved on: 
Tuesday, August 23, 2022
Russell Midcap Index, Hang Seng Composite Index Series, Hong, Hang Seng Index, Safety, Research, Hang Seng China Enterprises Index, Pulmonary fibrosis, Sino Biopharmaceutical Limited, Interim, Board, Hepatitis, ROCK2, Respiratory system, Medullary thyroid cancer, Liver disease, Flurbiprofen, III, Thyroid cancer, Clinical trial, Forbes, Growth, Analgesic, Marketing, Patient, Board of directors, Fine chemical, Pharmaceutical industry, Pneumoconiosis, Group, PRC

-- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.

Key Points: 
  • -- Focus V (Anlotinib Hydrochloride Capsules) was approved for the fifth indication-differentiated thyroid cancer in the first half of 2022.
  • During the Period, the Group recorded revenue of approximately RMB15.19 billion, an increase of approximately 5.9% against last year.
  • Sales of oncology medicines increased by 16.7% year-on-year to approximately 4.96 billion, accounting for approximately 32.6% of the Group's revenue.
  • Sino Biopharmaceutical Limited is a leading, innovative R&D-driven pharmaceutical conglomerate in the PRC.

Thyroid Cancer Drugs Global Market Research Report 2022: Focus on Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Pharmaceutical, Health, Oncology, FDA, Doxorubicin, Iodine, Patient, Goitre, Protein, GlaxoSmithKline, BRAF, Tissue, American Cancer Society, AstraZeneca, Trametinib, Death, Abbott, Man, Medullary thyroid cancer, Growth, Cancer, MTC, MEK, Disease, API, Thyroid cancer, THS, Baxter International, Cabozantinib, Woman, Drug resistance, Thyroidectomy, Food, Teva, Shanda, Radiation, Nivolumab, Survival, Ipilimumab, History of the Food and Drug Administration, Thyroid lymphoma, Hospital, Pharmaceutical industry, Medical imaging, Dietary supplement, Vandetanib

The "Thyroid Cancer Drugs Global Market Report 2022, Drug Type, End Users, Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Cancer Drugs Global Market Report 2022, Drug Type, End Users, Type" report has been added to ResearchAndMarkets.com's offering.
  • The thyroid cancer drugs market consists of sales of drugs that are used to treat thyroid cancer.
  • Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market.
  • Increasing use of targeted therapies for the treatment of thyroid cancer is acting as a restraint on the thyroid cancer drugs market.

FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

Retrieved on: 
Friday, May 13, 2022
Pancreatitis, Semaglutide, Constipation, Office of Inspector General, U.S. Department of Health and Human Services, Nausea, Center for Drug Evaluation and Research, Glucose, Blood, Neoplasm, History, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Research, Abdominal pain, Public health, A1C, Eli Lilly and Company, Exercise, Cosmetics, Patient, Multimedia, Vaccine, China Biologic Products, Human services, FDA, Type 2 diabetes, GIP, RATS, Appetite, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Center, Smokeless tobacco, Animal, Dietary supplement, Body mass index, Human, Diet, Medullary thyroid cancer, Insulin, Thyroid cancer, Vomiting, Safety, Division, Hormone, Obesity, Diagnosis, Weight loss, Diarrhea, Glycated hemoglobin, Pharmaceutical industry, Diabetes

SILVER SPRING, Md., May 13, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.   

Key Points: 
  • Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.
  • Type 2 diabetes, the most common form of diabetes, is a chronic and progressive condition in which the body does not make or use insulin normally, leading to high levels of glucose (sugar) in the blood.
  • More than 30 million Americans have type 2 diabetes.
  • Despite the availability of many medications to treat diabetes, many patients do not achieve the recommended blood sugar goals.